

Morquio Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/M78AA94244FFEN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: M78AA94244FFEN

Abstracts

The 7 major Morquio syndrome markets are expected to exhibit a CAGR of 4.45% during 2024-2034.

The Morquio syndrome market has been comprehensively analyzed in IMARC's new report titled "Morquio Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Morquio syndrome, also known as mucopolysaccharidosis type IV (MPS IV), refers to a rare genetic disorder caused by the deficiency or malfunctioning of enzymes involved in the breakdown of certain sugar molecules called glycosaminoglycans (GAGs). The most prominent symptoms associated with the ailment are short stature, skeletal abnormalities, joint laxity, pectus carinatum (protruding chest), hip dysplasia, etc. Various respiratory complications, like obstructive sleep apnea and restrictive lung disease, may also occur. Some other common indications include vision and hearing impairment, cardiac issues, dental problems, etc. The diagnosis of the ailment involves a combination of clinical evaluation, biochemical testing, genetic testing, and imaging studies. Clinical assessment may consist of a physical examination, evaluation of medical history, as well as identification of characteristic symptoms. Several biochemical tests, such as measuring GAGs or enzyme activity levels in blood or urine, aid in confirming the diagnosis. Genetic testing plays a crucial role in identifying specific gene mutations associated with Morquio syndrome. Additionally, numerous imaging studies, including X-rays, CT scans, MRIs, etc., help to visualize skeletal abnormalities and organ involvement.

The increasing cases of deficiency or malfunctioning of specific enzymes, such as N-acetylgalactosamine-6-sulfatase and beta-galactosidase, that disrupt normal tissue functioning are primarily driving the Morquio syndrome market. Furthermore, the rising

adoption of effective pain management strategies, including physical therapy, occupational therapy, medications, etc., to help alleviate pain and improve daily functioning in patients is acting as another significant growth-inducing factor. Additionally, the emerging popularity of enzyme replacement therapy (ERT), which involves administering a synthetic form of the deficient enzyme to replace the missing or dysfunctional enzyme responsible for breaking down GAGs, is also creating a positive outlook for the market. Moreover, the increasing utilization of orthopedic interventions, such as corrective surgeries and spinal fusion, for addressing the skeletal issues associated with the ailment, including short stature, skeletal deformities, joint abnormalities, etc., is further augmenting the market growth. Apart from this, the ongoing advancements in biomarker analysis techniques, such as the introduction of liquid chromatography-mass spectrometry (LC-MS) and enzyme-linked immunosorbent assay (ELISA), which have improved the accuracy and sensitivity of biomarker detection, are expected to drive the Morquio syndrome market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Morquio syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Morquio syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Morquio syndrome market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the Morquio syndrome market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the Morquio syndrome market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Morquio syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Morquio Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-20...

Market Insights

How has the Morquio syndrome market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the Morquio syndrome market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Morquio syndrome market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Morquio syndrome across the seven major markets?

What is the number of prevalent cases (2018-2034) of Morquio syndrome by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of Morquio syndrome by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with Morquio syndrome across the seven major markets?

What is the size of the Morquio syndrome patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Morquio syndrome?

What will be the growth rate of patients across the seven major markets?

Morquio Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Morquio syndrome drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Morquio syndrome market?

What are the key regulatory events related to the Morquio syndrome market?

What is the structure of clinical trial landscape by status related to the Morquio syndrome market?

What is the structure of clinical trial landscape by phase related to the Morquio syndrome market?

What is the structure of clinical trial landscape by route of administration related to the Morquio syndrome market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 MORQUIO SYNDROME - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 MORQUIO SYNDROME - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 MORQUIO SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 MORQUIO SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 MORQUIO SYNDROME - UNMET NEEDS

10 MORQUIO SYNDROME - KEY ENDPOINTS OF TREATMENT

11 MORQUIO SYNDROME - MARKETED PRODUCTS

- 11.1 List of Morquio Syndrome Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Vimizim (Elosulfase alfa) - BioMarin Pharmaceuticals
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 MORQUIO SYNDROME - PIPELINE DRUGS

12.1 List of Morquio Syndrome Pipeline Drugs Across the Top 7 Markets

12.1.1 Drug Name – Company Name

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. MORQUIO SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. MORQUIO SYNDROME – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 MORQUIO SYNDROME - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Morquio Syndrome - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Morquio Syndrome - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Morquio Syndrome - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Morquio Syndrome - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

- 15.3.3 Morquio Syndrome - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Morquio Syndrome - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Morquio Syndrome - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Morquio Syndrome - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Morquio Syndrome - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Morquio Syndrome - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Morquio Syndrome - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Morquio Syndrome - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Morquio Syndrome - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Morquio Syndrome - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Morquio Syndrome - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Morquio Syndrome - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Morquio Syndrome - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Morquio Syndrome - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Morquio Syndrome - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)

- 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Morquio Syndrome - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Morquio Syndrome - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Morquio Syndrome - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Morquio Syndrome - Access and Reimbursement Overview

16 MORQUIO SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 MORQUIO SYNDROME MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 MORQUIO SYNDROME MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Morquio Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/M78AA94244FFEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M78AA94244FFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

